X
NICE clears front-line NHS use for Pfizer’s lung cancer drug Vizimpro
https://pharmaphorum.com/news/nice-clears-front-line-nhs-use-for-pfizers-lung-cancer-drug-vizimpro/
Non-small cell lung cancer
Roche’s Tecentriq combo extends life in advanced NSCLC
Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
Evolving immunotherapy strategies in NSCLC
Status of immunotherapies in non-small cell lung cancer (NSCLC).